Analysis reveals changes in carbapenem-resistant enterobacterales, highlighting the implications for clinical treatment options.
Background: Carbapenem-resistant Enterobacterales (CRE) represent heterogeneous resistance mechanisms with distinct clinical and public health implications (1, 2). Among these mechanisms, carbapenemases drive the spread of CRE. The type of carbapenemase affects treatment options, as fewer agents are active against CRE with NDM (New Delhi metallo-β-lactamase) and other metallo-β-lactamases compared with KPC (Klebsiella pneumoniae carbapenemase), the historically predominant carbapenemase in U.S. CRE (3).Objective: We describe trends in carbapenemase-producing CRE (CP-CRE) clinical isolates reported to the Antimicrobial Resistance Laboratory Network of the Centers for Disease Control and Prevention (CDC) (4) from January 2019 through December 2023.Methods …
No takes yet. Share an insight, caveat, or question.
Rankin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: